The use of CA125, human epididymis protein 4 (HE4) , risk of ovarian malignancy algorithm (ROMA), risk of malignancy index (RMI) and subjective assessment (SA) in preoperative diagnosing of ovarian tumors

被引:0
|
作者
Janas, Lukasz [1 ]
Stachowiak, Grzegorz [1 ]
Glowacka, Ewa [2 ]
Piwowarczyk, Iwona [1 ]
Kajdos, Magdalena [1 ,3 ]
Soja, Malwina [1 ]
Masternak, Martyna [1 ]
Nowak, Marek [1 ,3 ]
机构
[1] Polish Mothers Mem Hosp Res Inst, Dept Operat Gynecol & Gynecol Oncol, Rzgowska St 281-289, PL-93338 Lodz, Poland
[2] Polish Mothers Mem Hosp Res Inst, Ctr Med Lab Diagnost, Lodz, Poland
[3] Med Univ Lodz, Dept Operat & Endoscop Gynecol, Lodz, Poland
关键词
serum tumor markers; preoperative assessment of adnexal mass; ovarian cancer; endometriosis; DIFFERENTIAL-DIAGNOSIS; MENOPAUSAL STATUS; CANCER; SERUM; BENIGN; ULTRASOUND; MARKER; PREDICTION; CYTOKINES; BIOMARKER;
D O I
暂无
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objectives: To compare utility of carcinoma antigen 125 (CA125), human epididymis protein 4 (HE4), risk of ovarian malignancy algorithm (ROMA), risk of malignancy index (RMI) and subjective assessment (SA) in preoperative diagnosis of ovarian tumors. Material and methods: Research was conducted among 456 patients qualified for surgery due to ovarian tumor. Preoperatively, CA125 and HE4 serum levels were estimated, and transvaginal ultrasound was performed. ROMA and RMI values and SA qualifications were obtained. Results were compared with pathomorphological findings. Results: Receiver operating characteristic (ROC) -area under curve (AUC) values for CA125, HE4, ROMA, RMI and SA in preoperative diagnosis of malignant lesions were 0.819, 0.909, 0.911, 0.895 and 0.895, respectively. Combinations of biochemical and sonographic methods increased sensitivity in diagnosis of ovarian tumors. Combinations utilizing serum HE4 concentrations were most useful. Conclusions: CA125, HE4, ROMA, RMI and SA proved to be useful in preoperative diagnosis of ovarian tumors. HE4 and ROMA occurred to be the most useful. Ultrasonographic methods are considerably useful in diagnosis of ovarian tumors. RMI and SA present similar overall diagnostic value.
引用
收藏
页码:321 / 327
页数:7
相关论文
共 50 条
  • [1] The use of CA125, human epididymis protein 4 (HE4) , risk of ovarian malignancy algorithm (ROMA), risk of malignancy index (RMI) and subjective assessment (SA) in preoperative diagnosing of ovarian tumors
    Janas, Lukas
    Stachowiak, Grzegorz
    Glowacka, Ewa
    Piwowarczyk, Iwona
    Kajdos, Magdalena
    Soja, Malwina
    Masternak, Martyna
    Nowak, Marek
    GINEKOLOGIA POLSKA, 2022,
  • [2] Cancer Antigen 125 (CA125), Human Epididymis Protein 4 (HE4), Risk of Malignancy Index (RMI), and Risk of Ovarian Malignancy Algorithm (ROMA) as Diagnostic Tests in Ovarian Cancer
    Bouzari, Zinatossadat
    Rahimi, Hadiseh
    Gholinia, Hemmat
    Yazdani, Shahla
    Hajian-Tilaki, Karimollah
    Soleimani, Mohammad Jafar
    INTERNATIONAL JOURNAL OF CANCER MANAGEMENT, 2019, 12 (01)
  • [3] Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass
    Karlsen, Mona Aarenstrup
    Sandhu, Noreen
    Hogdall, Claus
    Christensen, Ib Janie
    Nedergaard, Lotte
    Lundvall, Lene
    Engelholm, Svend A.
    Pedersen, Anette T.
    Hartwell, Dorthe
    Lydolph, Magnus
    Laursen, Inga Alice
    Hegdall, Estrid V. S.
    GYNECOLOGIC ONCOLOGY, 2012, 127 (02) : 379 - 383
  • [4] Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial
    Dochez, Vincent
    Randet, Melanie
    Renaudeau, Celine
    Dimet, Jerome
    Le Thuaut, Aurelie
    Winer, Norbert
    Thubert, Thibault
    Vaucel, Edouard
    Caillon, Helene
    Ducarme, Guillaume
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (11)
  • [5] A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index
    Lycke, Maria
    Kristjansdottir, Bjorg
    Sundfeldt, Karin
    GYNECOLOGIC ONCOLOGY, 2018, 151 (01) : 159 - 165
  • [6] Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125
    Chudecka-Glaz, Anita
    Cymbaluk-Ploska, Aneta
    Luterek-Puszynska, Katarzyna
    Menkiszak, Janusz
    ONCOLOGY LETTERS, 2016, 12 (05) : 3101 - 3114
  • [7] Modification of Cutoff Values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for Ovarian Cancer Detection in Jakarta, Indonesia
    Winarto, Hariyono
    Laihad, Bismarck Joel
    Nuranna, Laila
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (05) : 1949 - 1953
  • [8] HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm
    Van Gorp, T.
    Cadron, I.
    Despierre, E.
    Daemen, A.
    Leunen, K.
    Amant, F.
    Timmerman, D.
    De Moor, B.
    Vergote, I.
    BRITISH JOURNAL OF CANCER, 2011, 104 (05) : 863 - 870
  • [9] HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study
    Romagnolo, Cesare
    Leon, Antonette E.
    Fabricio, Aline S. C.
    Taborelli, Martina
    Polesel, Jerry
    Del Pup, Lino
    Steffan, Agostino
    Cervo, Silvia
    Ravaggi, Antonella
    Zanotti, Laura
    Bandiera, Elisabetta
    Odicino, Franco E.
    Scattolo, Novella
    Squarcina, Elisa
    Papadakis, Christine
    Maggino, Tiziano
    Gion, Massimo
    GYNECOLOGIC ONCOLOGY, 2016, 141 (02) : 303 - 311
  • [10] The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4
    Han, Kyung Hee
    Park, Noh Hyun
    Kim, Jin Ju
    Kim, Sunmie
    Kim, Hee Seung
    Lee, Maria
    Song, Yong Sang
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 30 (06)